PTC Therapeutics | PTCT - Cash And Equivalent


PTC Therapeutics reported $984.65M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Cytokinetics USD 122.52M 102.95M Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xencor USD 54.07M 25.78M Dec/2025